logo

Enabling Surgical Pocket REgeneration

Sector: Hospital • Location: Switzerland

Source: EU Funding & Tenders Portal

Project
Ended

All medical devices implanted into the human body are perceived as foreign objects resulting in an attempt by the body to reject them through a process called foreign body reaction. This can result in either the failure of the medical device and/or significant clinical complications. Hylomorph has developed Hylomate®, the world’s first solution to protect all implantable medical devices in contact

Project Information FAQ

Project Information

3 Q
The project “Enabling Surgical Pocket REgeneration” is an infrastructure initiative in the Hospital sector, located in Switzerland. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Want to explore the full details? View the full report

Participants

Sponsoring Agency

Obfuscated Data

Company

Obfuscated Data

Status

Original status

ended

Taiyo status

Obfuscated Data

Taiyo last update

00-00-0000

Available timestamps

00-00-0000

Available timestamp type

Obfuscated Data

Contact

Contact name

Obfuscated Data

Phone

0000000000

Email

ObfuscatedData@email.com

Address

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Description

Description

All medical devices implanted into the human body are perceived as foreign objects resulting in an attempt by the body to reject them through a process called foreign body reaction. This can result in either the failure of the medical device and/or significant clinical complications. Hylomorph has developed Hylomate®, the world’s first solution to protect all implantable medical devices in contact with soft tissues from foreign body reaction, acting as an “invisibility” cloak through complex interactions at the microscopic level with the surrounding tissue. Hylomate® is a platform technology that addresses all causes of severe complications connected to the implantation of synthetic materials. It ensures an all-round protection of the surgical pocket, preventing infection, hematoma, foreign body reaction and fibrotic encapsulation. Hylomate® increases the lifespan of implants and minimizes exposure to life-threatening risks. This results in (1) improved quality-of-life for patients, (2) better quality-of-care for healthcare providers and (3) reduced health economics burdens. The first application for Hylomate® will be in the field of cardiac rhythm management in combination with pacemakers, implantable cardioverter defibrillators, and cardiac resynchronization therapy devices. Other applications are currently under development in the field of breast reconstruction, aesthetics and nerve repair.

Original sub-sector

Obfuscated

Original Currency

USD

Original budget

000000000000000

Procurement method

Obfuscated Data

Budget

000000000000000

Location

Region

Obfuscated

Country

Obfuscated

State

Obfuscated Data

County

Obfuscated

Location

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Source

Source reliability

High

Data quality score

100%

Source

Obfuscated Data

URL

obfuscated_data,obfuscateddata.com

More Details

Project Type

Obfuscated Data

Article Published Date

Obfuscated Data